Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578 + letrozole + CDK4/6 inhibitor in HR+/HER2- breast cancer
NCT06570031Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-4578 in breast cancer (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Adverse events, Serious adverse events and 11 more. Started Nov 2021; status: completed.
02
Drugs
ONO-4578
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06570031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06570031.